Question 1: Does the use of ranitidine increase the risk of NEC in preterm infants?
- 13 March 2014
- journal article
- review article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 99 (4) , 390-392
Abstract
The consultant questioned the risk of necrotising enterocolitis (NEC) with the use of ranitidine.Keywords
This publication has 14 references indexed in Scilit:
- H2-blocker Therapy and Incidence of Necrotizing Enterocolitis in Preterm Infants: A Case-control StudyPediatrics & Neonatology, 2013
- Ranitidine is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in NewbornsPediatrics, 2012
- Necrotizing EnterocolitisNew England Journal of Medicine, 2011
- Use of Medications for Gastroesophageal Reflux at Discharge Among Extremely Low Birth Weight InfantsPediatrics, 2008
- Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight InfantsPediatrics, 2006
- Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: An open-label, multiple-dose, randomized, multicenter clinical trial in 210 childrenClinical Therapeutics, 2005
- Famotidine for infant gastro‐oesophageal reflux: a multi‐centre, randomized, placebo‐controlled, withdrawal trialAlimentary Pharmacology & Therapeutics, 2003
- Long term gastric pH monitoring for determining optimal dose of ranitidine for critically ill preterm and term neonatesArchives of Disease in Childhood - Fetal and Neonatal Edition, 1998
- Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis.Archives of Disease in Childhood, 1993
- Prevention of Neonatal Necrotizing EnterocolitisJournal of Pediatric Gastroenterology and Nutrition, 1990